Physician profile
Scott Brown
NPI 1801960984
$947.20
in general payments reported to CMS, 2019-2025
12 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.15 · 2020: $55.49 · 2021: $21.25 · 2023: $147 · 2024: $396 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $337.29 | 2024-2025 | Repatha, Otezla, Repatha |
| Aimmune Therapeutics, INC. | $105.47 | 2024 | |
| Novo Nordisk INC | $90.14 | 2020-2025 | Ozempic, Rybelsus |
| Indivior INC. | $70.69 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $68.43 | 2023-2024 | Farxiga |
| Biodelivery Sciences International, INC. | $64.46 | 2019-2020 | |
| Abbvie INC. | $61.11 | 2025 | |
| Esperion Therapeutics, INC. | $40.54 | 2023 | Nexletol |
| Lilly USA, LLC | $40.08 | 2023 | Mounjaro |
| Telix Pharmaceuticals | $36.37 | 2023 | Illuccix |
| Bioventus LLC | $19.70 | 2019 | |
| Exact Sciences Corporation | $12.92 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.